Financhill
Sell
41

MBRX Quote, Financials, Valuation and Earnings

Last price:
$0.64
Seasonality move :
-13.58%
Day range:
$0.61 - $0.73
52-week range:
$0.25 - $4.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
211.48x
Volume:
3.6M
Avg. volume:
8.8M
1-year change:
-85.12%
Market cap:
$8.9M
Revenue:
--
EPS (TTM):
-$4.73

Analysts' Opinion

  • Consensus Rating
    Moleculin Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $7.00, Moleculin Biotech has an estimated upside of 1013.41% from its current price of $0.63.
  • Price Target Downside
    According to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.63.

Fair Value

  • According to the consensus of 1 analyst, Moleculin Biotech has 1013.41% upside to fair value with a price target of $7.00 per share.

MBRX vs. S&P 500

  • Over the past 5 trading days, Moleculin Biotech has overperformed the S&P 500 by 21.29% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Moleculin Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Moleculin Biotech has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Moleculin Biotech reported revenues of --.

Earnings Growth

  • Moleculin Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Moleculin Biotech reported earnings per share of -$0.69.
Enterprise value:
1.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$31.9M -$28M -$25.9M -$6.7M -$5.9M
EBITDA -$31.8M -$27.8M -$25.8M -$6.6M -$5.9M
Diluted EPS -$15.83 -$12.99 -$4.73 -$2.02 -$0.69
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $88M $67.3M $39.3M $19M $9.3M
Total Assets $99.8M $78.8M $51.1M $30.8M $21M
Current Liabilities $4.6M $4.8M $5M $5.4M $6.9M
Total Liabilities $11.3M $6.1M $5.4M $9.3M $21M
Total Equity $88.5M $72.7M $45.7M $21.6M $42K
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$28.9M -$24.3M -$21.7M -$6.7M -$4.6M
Cash From Investing -- -$124K -$13K -- --
Cash From Financing $118K $4M $12.6M -- $8M
Free Cash Flow -$28.9M -$24.4M -$21.7M -$6.7M -$4.6M
MBRX
Sector
Market Cap
$8.9M
$34.5M
Price % of 52-Week High
13.36%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-85.12%
-35.15%
Beta (5-Year)
1.381
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $0.52
200-day SMA
Sell
Level $1.51
Bollinger Bands (100)
Sell
Level 0.61 - 1.15
Chaikin Money Flow
Sell
Level -44M
20-day SMA
Buy
Level $0.44
Relative Strength Index (RSI14)
Buy
Level 57.46
ADX Line
Buy
Level 31.53
Williams %R
Neutral
Level -21.6404
50-day SMA
Sell
Level $0.71
MACD (12, 26)
Buy
Level 0.16
25-day Aroon Oscillator
Sell
Level -4
On Balance Volume
Neutral
Level 132.5M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Stock Forecast FAQ

In the current month, MBRX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBRX average analyst price target in the past 3 months is $7.00.

  • Where Will Moleculin Biotech Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Moleculin Biotech share price will rise to $7.00 per share over the next 12 months.

  • What Do Analysts Say About Moleculin Biotech?

    Analysts are divided on their view about Moleculin Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moleculin Biotech is a Sell and believe this share price will drop from its current level to $4.00.

  • What Is Moleculin Biotech's Price Target?

    The price target for Moleculin Biotech over the next 1-year time period is forecast to be $7.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MBRX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Moleculin Biotech is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of MBRX?

    You can purchase shares of Moleculin Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moleculin Biotech shares.

  • What Is The Moleculin Biotech Share Price Today?

    Moleculin Biotech was last trading at $0.64 per share. This represents the most recent stock quote for Moleculin Biotech. Yesterday, Moleculin Biotech closed at $0.63 per share.

  • How To Buy Moleculin Biotech Stock Online?

    In order to purchase Moleculin Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
78
SBET alert for Jul 16

SharpLink Gaming [SBET] is up 28.58% over the past day.

Buy
75
MP alert for Jul 16

MP Materials [MP] is up 0.48% over the past day.

Sell
38
NAIL alert for Jul 16

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 2.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock